Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 421 to 429 of 429 entries
Sorted by: Best Match Show Resources per page
NUDT15 polymorphism and NT5C2 and PRPS1 mutations influence thiopurine sensitivity in acute lymphoblastic leukaemia cells.

Journal of cellular and molecular medicine

Somazu S, Tanaka Y, Tamai M, Watanabe A, Kagami K, Abe M, Harama D, Shinohara T, Akahane K, Goi K, Sugita K, Moriyama T, Yang J, Goto H, Minegishi M, Iwamoto S, Takita J, Inukai T.
PMID: 34636169
J Cell Mol Med. 2021 Nov;25(22):10521-10533. doi: 10.1111/jcmm.16981. Epub 2021 Oct 12.

In chemotherapy for childhood acute lymphoblastic leukaemia (ALL), maintenance therapy consisting of oral daily mercaptopurine and weekly methotrexate is important. NUDT15 variant genotype is reportedly highly associated with severe myelosuppression during maintenance therapy, particularly in Asian and Hispanic populations....

Cite
Somazu S, Tanaka Y, Tamai M, et al. NUDT15 polymorphism and NT5C2 and PRPS1 mutations influence thiopurine sensitivity in acute lymphoblastic leukaemia cells. J Cell Mol Med. 2021;25(22):10521-10533doi: 10.1111/jcmm.16981.
Somazu, S., Tanaka, Y., Tamai, M., Watanabe, A., Kagami, K., Abe, M., Harama, D., Shinohara, T., Akahane, K., Goi, K., Sugita, K., Moriyama, T., Yang, J., Goto, H., Minegishi, M., Iwamoto, S., Takita, J., & Inukai, T. (2021). NUDT15 polymorphism and NT5C2 and PRPS1 mutations influence thiopurine sensitivity in acute lymphoblastic leukaemia cells. Journal of cellular and molecular medicine, 25(22), 10521-10533. https://doi.org/10.1111/jcmm.16981
Somazu, Shinpei, et al. "NUDT15 polymorphism and NT5C2 and PRPS1 mutations influence thiopurine sensitivity in acute lymphoblastic leukaemia cells." Journal of cellular and molecular medicine vol. 25,22 (2021): 10521-10533. doi: https://doi.org/10.1111/jcmm.16981
Somazu S, Tanaka Y, Tamai M, Watanabe A, Kagami K, Abe M, Harama D, Shinohara T, Akahane K, Goi K, Sugita K, Moriyama T, Yang J, Goto H, Minegishi M, Iwamoto S, Takita J, Inukai T. NUDT15 polymorphism and NT5C2 and PRPS1 mutations influence thiopurine sensitivity in acute lymphoblastic leukaemia cells. J Cell Mol Med. 2021 Nov;25(22):10521-10533. doi: 10.1111/jcmm.16981. Epub 2021 Oct 12. PMID: 34636169; PMCID: PMC8581340.
Copy Download .nbib Format: NLM
Mid- to Long-Term Outcomes After Resection of Thoracic Dumbbell Tumors Managed by Laminectomy and Unilateral Total Facetectomy Without Instrumented Fusion.

Global spine journal

Ishikawa Y, Ohashi M, Hirano T, Matsuda M, Akabane T, Kanno H, Hashimoto K, Handa K, Aizawa T, Suzuki T, Shimamura Y, Watanabe K.
PMID: 33973481
Global Spine J. 2021 May 11;21925682211008836. doi: 10.1177/21925682211008836. Epub 2021 May 11.

STUDY DESIGN: Retrospective multicenter study.OBJECTIVE: To evaluate mid- to long-term surgical outcomes of thoracic dumbbell tumors managed by laminectomy and unilateral total facetectomy without instrumented fusion.METHODS: A total of 15 patients with thoracic dumbbell tumors who underwent primary resection...

Cite
Ishikawa Y, Ohashi M, Hirano T, et al. Mid- to Long-Term Outcomes After Resection of Thoracic Dumbbell Tumors Managed by Laminectomy and Unilateral Total Facetectomy Without Instrumented Fusion. Global Spine J. 2021;21925682211008836doi: 10.1177/21925682211008836.
Ishikawa, Y., Ohashi, M., Hirano, T., Matsuda, M., Akabane, T., Kanno, H., Hashimoto, K., Handa, K., Aizawa, T., Suzuki, T., Shimamura, Y., & Watanabe, K. (2021). Mid- to Long-Term Outcomes After Resection of Thoracic Dumbbell Tumors Managed by Laminectomy and Unilateral Total Facetectomy Without Instrumented Fusion. Global spine journal, 21925682211008836. https://doi.org/10.1177/21925682211008836
Ishikawa, Yuya, et al. "Mid- to Long-Term Outcomes After Resection of Thoracic Dumbbell Tumors Managed by Laminectomy and Unilateral Total Facetectomy Without Instrumented Fusion." Global spine journal vol. (2021): 21925682211008836. doi: https://doi.org/10.1177/21925682211008836
Ishikawa Y, Ohashi M, Hirano T, Matsuda M, Akabane T, Kanno H, Hashimoto K, Handa K, Aizawa T, Suzuki T, Shimamura Y, Watanabe K. Mid- to Long-Term Outcomes After Resection of Thoracic Dumbbell Tumors Managed by Laminectomy and Unilateral Total Facetectomy Without Instrumented Fusion. Global Spine J. 2021 May 11;21925682211008836. doi: 10.1177/21925682211008836. Epub 2021 May 11. PMID: 33973481.
Copy Download .nbib Format: NLM
Developing diagnostic reference levels in Japan.

Japanese journal of radiology

Kanda R, Akahane M, Koba Y, Chang W, Akahane K, Okuda Y, Hosono M.
PMID: 33211263
Jpn J Radiol. 2021 Apr;39(4):307-314. doi: 10.1007/s11604-020-01066-5. Epub 2020 Nov 19.

No abstract available.

Cite
Kanda R, Akahane M, Koba Y, et al. Developing diagnostic reference levels in Japan. Jpn J Radiol. 2020;39(4):307-314doi: 10.1007/s11604-020-01066-5.
Kanda, R., Akahane, M., Koba, Y., Chang, W., Akahane, K., Okuda, Y., & Hosono, M. (2021). Developing diagnostic reference levels in Japan. Japanese journal of radiology, 39(4), 307-314. https://doi.org/10.1007/s11604-020-01066-5
Kanda, Reiko, et al. "Developing diagnostic reference levels in Japan." Japanese journal of radiology vol. 39,4 (2021): 307-314. doi: https://doi.org/10.1007/s11604-020-01066-5
Kanda R, Akahane M, Koba Y, Chang W, Akahane K, Okuda Y, Hosono M. Developing diagnostic reference levels in Japan. Jpn J Radiol. 2021 Apr;39(4):307-314. doi: 10.1007/s11604-020-01066-5. Epub 2020 Nov 19. PMID: 33211263; PMCID: PMC8019674.
Copy Download .nbib Format: NLM
CN470 is a BET/CBP/p300 multi-bromodomain inhibitor and has an anti-tumor activity against MLL-rearranged acute lymphoblastic leukemia.

Biochemical and biophysical research communications

Imayoshi N, Yoshioka M, Tanaka K, Yang SM, Akahane K, Toda Y, Hosogi S, Inukai T, Okada S, Maloney DJ, Nakahata T, Takita J, Kato I, Ashihara E.
PMID: 34971957
Biochem Biophys Res Commun. 2021 Dec 24;590:49-54. doi: 10.1016/j.bbrc.2021.12.078. Epub 2021 Dec 24.

Acute lymphoblastic leukemia with chromosomal rearrangements involving the mixed-lineage leukemia (MLL) gene (MLL-r ALL) remains an incurable disease. Thus, development of a safe and effective therapeutic agent to treat this disease is crucial to address this unmet medical need....

Cite
Imayoshi N, Yoshioka M, Tanaka K, et al. CN470 is a BET/CBP/p300 multi-bromodomain inhibitor and has an anti-tumor activity against MLL-rearranged acute lymphoblastic leukemia. Biochem Biophys Res Commun. 2021;590:49-54doi: 10.1016/j.bbrc.2021.12.078.
Imayoshi, N., Yoshioka, M., Tanaka, K., Yang, S. M., Akahane, K., Toda, Y., Hosogi, S., Inukai, T., Okada, S., Maloney, D. J., Nakahata, T., Takita, J., Kato, I., & Ashihara, E. (2021). CN470 is a BET/CBP/p300 multi-bromodomain inhibitor and has an anti-tumor activity against MLL-rearranged acute lymphoblastic leukemia. Biochemical and biophysical research communications, 59049-54. https://doi.org/10.1016/j.bbrc.2021.12.078
Imayoshi, Natsuki, et al. "CN470 is a BET/CBP/p300 multi-bromodomain inhibitor and has an anti-tumor activity against MLL-rearranged acute lymphoblastic leukemia." Biochemical and biophysical research communications vol. 590 (2021): 49-54. doi: https://doi.org/10.1016/j.bbrc.2021.12.078
Imayoshi N, Yoshioka M, Tanaka K, Yang SM, Akahane K, Toda Y, Hosogi S, Inukai T, Okada S, Maloney DJ, Nakahata T, Takita J, Kato I, Ashihara E. CN470 is a BET/CBP/p300 multi-bromodomain inhibitor and has an anti-tumor activity against MLL-rearranged acute lymphoblastic leukemia. Biochem Biophys Res Commun. 2021 Dec 24;590:49-54. doi: 10.1016/j.bbrc.2021.12.078. Epub 2021 Dec 24. PMID: 34971957.
Copy Download .nbib Format: NLM
Angiotensin Receptor Blockers Potentiate the Protective Effect of Branched-Chain Amino Acids on Skeletal Muscle Atrophy in Cirrhotic Rats.

Molecular nutrition & food research

Takeda S, Kaji K, Nishimura N, Enomoto M, Fujimoto Y, Murata K, Takaya H, Kawaratani H, Moriya K, Namisaki T, Akahane T, Yoshiji H.
PMID: 34687151
Mol Nutr Food Res. 2021 Oct 22;e2100526. doi: 10.1002/mnfr.202100526. Epub 2021 Oct 22.

SCOPE: This study investigated the combined effect of the angiotensin II (AT-II) receptor blocker losartan and branched-chain amino acids (BCAAs) on skeletal muscle atrophy in rats with cirrhosis and steatohepatitis.METHOD AND RESULTS: Fischer 344 rats are fed a choline-deficient...

Cite
Takeda S, Kaji K, Nishimura N, et al. Angiotensin Receptor Blockers Potentiate the Protective Effect of Branched-Chain Amino Acids on Skeletal Muscle Atrophy in Cirrhotic Rats. Mol Nutr Food Res. 2021;e2100526doi: 10.1002/mnfr.202100526.
Takeda, S., Kaji, K., Nishimura, N., Enomoto, M., Fujimoto, Y., Murata, K., Takaya, H., Kawaratani, H., Moriya, K., Namisaki, T., Akahane, T., & Yoshiji, H. (2021). Angiotensin Receptor Blockers Potentiate the Protective Effect of Branched-Chain Amino Acids on Skeletal Muscle Atrophy in Cirrhotic Rats. Molecular nutrition & food research, e2100526. https://doi.org/10.1002/mnfr.202100526
Takeda, Soichi, et al. "Angiotensin Receptor Blockers Potentiate the Protective Effect of Branched-Chain Amino Acids on Skeletal Muscle Atrophy in Cirrhotic Rats." Molecular nutrition & food research vol. (2021): e2100526. doi: https://doi.org/10.1002/mnfr.202100526
Takeda S, Kaji K, Nishimura N, Enomoto M, Fujimoto Y, Murata K, Takaya H, Kawaratani H, Moriya K, Namisaki T, Akahane T, Yoshiji H. Angiotensin Receptor Blockers Potentiate the Protective Effect of Branched-Chain Amino Acids on Skeletal Muscle Atrophy in Cirrhotic Rats. Mol Nutr Food Res. 2021 Oct 22;e2100526. doi: 10.1002/mnfr.202100526. Epub 2021 Oct 22. PMID: 34687151.
Copy Download .nbib Format: NLM
Comparison of Clinical Outcomes of Definitive and Postoperative Radiotherapy for Adenoid Cystic Carcinoma of the Head and Neck: Can Definitive Radiotherapy Be a Treatment Option?.

Cancers

Mizoguchi N, Kano K, Shima S, Tsuchida K, Takakusagi Y, Serizawa I, Akahane K, Kawahara M, Yoshida M, Kitani Y, Hashimoto K, Furukawa M, Kamada T, Katoh H, Yoshida D, Shirai K.
PMID: 34771670
Cancers (Basel). 2021 Nov 02;13(21). doi: 10.3390/cancers13215507.

BACKGROUND: The standard treatment for adenoid cystic carcinoma of the head and neck is surgical resection followed by postoperative radiotherapy (PORT). Currently, definitive radiotherapy (defRT) is considered an inadequate treatment; however, its data are based on studies using classical...

Cite
Mizoguchi N, Kano K, Shima S, et al. Comparison of Clinical Outcomes of Definitive and Postoperative Radiotherapy for Adenoid Cystic Carcinoma of the Head and Neck: Can Definitive Radiotherapy Be a Treatment Option?. Cancers (Basel). 2021;13(21)doi: 10.3390/cancers13215507.
Mizoguchi, N., Kano, K., Shima, S., Tsuchida, K., Takakusagi, Y., Serizawa, I., Akahane, K., Kawahara, M., Yoshida, M., Kitani, Y., Hashimoto, K., Furukawa, M., Kamada, T., Katoh, H., Yoshida, D., & Shirai, K. (2021). Comparison of Clinical Outcomes of Definitive and Postoperative Radiotherapy for Adenoid Cystic Carcinoma of the Head and Neck: Can Definitive Radiotherapy Be a Treatment Option?. Cancers, 13(21), . https://doi.org/10.3390/cancers13215507
Mizoguchi, Nobutaka, et al. "Comparison of Clinical Outcomes of Definitive and Postoperative Radiotherapy for Adenoid Cystic Carcinoma of the Head and Neck: Can Definitive Radiotherapy Be a Treatment Option?." Cancers vol. 13,21 (2021). doi: https://doi.org/10.3390/cancers13215507
Mizoguchi N, Kano K, Shima S, Tsuchida K, Takakusagi Y, Serizawa I, Akahane K, Kawahara M, Yoshida M, Kitani Y, Hashimoto K, Furukawa M, Kamada T, Katoh H, Yoshida D, Shirai K. Comparison of Clinical Outcomes of Definitive and Postoperative Radiotherapy for Adenoid Cystic Carcinoma of the Head and Neck: Can Definitive Radiotherapy Be a Treatment Option?. Cancers (Basel). 2021 Nov 02;13(21). doi: 10.3390/cancers13215507. PMID: 34771670; PMCID: PMC8582871.
Copy Download .nbib Format: NLM
Reduction of bleeding complications on puncture site after percutaneous coronary intervention using a 6.5-French sheathless guiding catheter.

Heart and vessels

Akioka H, Yufu K, Harada T, Akamine K, Uemura T, Takahashi M, Nishimizu K, Hirota K, Ishii Y, Kira S, Yonezu K, Abe I, Tawara K, Kondo H, Saito S, Fukui A, Okada N, Shinohara T, Teshima Y, Nakagawa M, Takahashi N.
PMID: 35022882
Heart Vessels. 2022 Jan 13; doi: 10.1007/s00380-021-02005-8. Epub 2022 Jan 13.

BACKGROUND: Reducing complications at the puncture site after percutaneous coronary intervention (PCI) is important. The diameter of a 6.5-French (Fr) sheathless guiding catheter (GC) is smaller by approximately 2-Fr compared to a 6-Fr conventional sheath. In the present study,...

Cite
Akioka H, Yufu K, Harada T, et al. Reduction of bleeding complications on puncture site after percutaneous coronary intervention using a 6.5-French sheathless guiding catheter. Heart Vessels. 2022;doi: 10.1007/s00380-021-02005-8.
Akioka, H., Yufu, K., Harada, T., Akamine, K., Uemura, T., Takahashi, M., Nishimizu, K., Hirota, K., Ishii, Y., Kira, S., Yonezu, K., Abe, I., Tawara, K., Kondo, H., Saito, S., Fukui, A., Okada, N., Shinohara, T., Teshima, Y., Nakagawa, M., & Takahashi, N. (2022). Reduction of bleeding complications on puncture site after percutaneous coronary intervention using a 6.5-French sheathless guiding catheter. Heart and vessels, . https://doi.org/10.1007/s00380-021-02005-8
Akioka, Hidefumi, et al. "Reduction of bleeding complications on puncture site after percutaneous coronary intervention using a 6.5-French sheathless guiding catheter." Heart and vessels vol. (2022). doi: https://doi.org/10.1007/s00380-021-02005-8
Akioka H, Yufu K, Harada T, Akamine K, Uemura T, Takahashi M, Nishimizu K, Hirota K, Ishii Y, Kira S, Yonezu K, Abe I, Tawara K, Kondo H, Saito S, Fukui A, Okada N, Shinohara T, Teshima Y, Nakagawa M, Takahashi N. Reduction of bleeding complications on puncture site after percutaneous coronary intervention using a 6.5-French sheathless guiding catheter. Heart Vessels. 2022 Jan 13; doi: 10.1007/s00380-021-02005-8. Epub 2022 Jan 13. PMID: 35022882.
Copy Download .nbib Format: NLM
Molecular Evaluation of Endometrial Dedifferentiated Carcinoma, Endometrioid Carcinoma, Carcinosarcoma, and Serous Carcinoma Using a Custom-Made Small Cancer Panel.

Pathology oncology research : POR

Kobayashi Y, Kitazono I, Akahane T, Yanazume S, Kamio M, Togami S, Nohara S, Sakamoto I, Yokoyama S, Tabata K, Kobayashi H, Tanimoto A.
PMID: 35002543
Pathol Oncol Res. 2021 Dec 23;27:1610013. doi: 10.3389/pore.2021.1610013. eCollection 2021.

It is often difficult to histologically differentiate among endometrial dedifferentiated carcinoma (DC), endometrioid carcinoma (EC), serous carcinoma (SC), and carcinosarcoma (CS) due to the presence of solid components. In this study, we aimed to categorize these carcinomas according to...

Cite
Kobayashi Y, Kitazono I, Akahane T, et al. Molecular Evaluation of Endometrial Dedifferentiated Carcinoma, Endometrioid Carcinoma, Carcinosarcoma, and Serous Carcinoma Using a Custom-Made Small Cancer Panel. Pathol Oncol Res. 2021;27:1610013doi: 10.3389/pore.2021.1610013.
Kobayashi, Y., Kitazono, I., Akahane, T., Yanazume, S., Kamio, M., Togami, S., Nohara, S., Sakamoto, I., Yokoyama, S., Tabata, K., Kobayashi, H., & Tanimoto, A. (2021). Molecular Evaluation of Endometrial Dedifferentiated Carcinoma, Endometrioid Carcinoma, Carcinosarcoma, and Serous Carcinoma Using a Custom-Made Small Cancer Panel. Pathology oncology research : POR, 271610013. https://doi.org/10.3389/pore.2021.1610013
Kobayashi, Yusuke, et al. "Molecular Evaluation of Endometrial Dedifferentiated Carcinoma, Endometrioid Carcinoma, Carcinosarcoma, and Serous Carcinoma Using a Custom-Made Small Cancer Panel." Pathology oncology research : POR vol. 27 (2021): 1610013. doi: https://doi.org/10.3389/pore.2021.1610013
Kobayashi Y, Kitazono I, Akahane T, Yanazume S, Kamio M, Togami S, Nohara S, Sakamoto I, Yokoyama S, Tabata K, Kobayashi H, Tanimoto A. Molecular Evaluation of Endometrial Dedifferentiated Carcinoma, Endometrioid Carcinoma, Carcinosarcoma, and Serous Carcinoma Using a Custom-Made Small Cancer Panel. Pathol Oncol Res. 2021 Dec 23;27:1610013. doi: 10.3389/pore.2021.1610013. eCollection 2021. PMID: 35002543; PMCID: PMC8734147.
Copy Download .nbib Format: NLM
Targeting MEF2D-fusion Oncogenic Transcriptional Circuitries in B-cell Precursor Acute Lymphoblastic Leukemia.

Blood cancer discovery

Tsuzuki S, Yasuda T, Kojima S, Kawazu M, Akahane K, Inukai T, Imaizumi M, Morishita T, Miyamura K, Ueno T, Karnan S, Ota A, Hyodo T, Konishi H, Sanada M, Nagai H, Horibe K, Tomita A, Suzuki K, Muramatsu H, Takahashi Y, Miyazaki Y, Matsumura I, Kiyoi H, Hosokawa Y, Mano H, Hayakawa F.
PMID: 35015692
Blood Cancer Discov. 2020 Jul;1(1):82-95. doi: 10.1158/2643-3230.BCD-19-0080. Epub 2020 Jun 10.

The cellular context that integrates gene expression, signaling, and metabolism dictates the oncogenic behavior and shapes the treatment responses in distinct cancer types. Although chimeric fusion proteins involving transcription factors (TF) are hallmarks of many types of acute lymphoblastic...

Cite
Tsuzuki S, Yasuda T, Kojima S, et al. Targeting MEF2D-fusion Oncogenic Transcriptional Circuitries in B-cell Precursor Acute Lymphoblastic Leukemia. Blood Cancer Discov. 2020;1(1):82-95doi: 10.1158/2643-3230.BCD-19-0080.
Tsuzuki, S., Yasuda, T., Kojima, S., Kawazu, M., Akahane, K., Inukai, T., Imaizumi, M., Morishita, T., Miyamura, K., Ueno, T., Karnan, S., Ota, A., Hyodo, T., Konishi, H., Sanada, M., Nagai, H., Horibe, K., Tomita, A., Suzuki, K., Muramatsu, H., Takahashi, Y., Miyazaki, Y., Matsumura, I., Kiyoi, H., Hosokawa, Y., Mano, H., & Hayakawa, F. (2020). Targeting MEF2D-fusion Oncogenic Transcriptional Circuitries in B-cell Precursor Acute Lymphoblastic Leukemia. Blood cancer discovery, 1(1), 82-95. https://doi.org/10.1158/2643-3230.BCD-19-0080
Tsuzuki, Shinobu, et al. "Targeting MEF2D-fusion Oncogenic Transcriptional Circuitries in B-cell Precursor Acute Lymphoblastic Leukemia." Blood cancer discovery vol. 1,1 (2020): 82-95. doi: https://doi.org/10.1158/2643-3230.BCD-19-0080
Tsuzuki S, Yasuda T, Kojima S, Kawazu M, Akahane K, Inukai T, Imaizumi M, Morishita T, Miyamura K, Ueno T, Karnan S, Ota A, Hyodo T, Konishi H, Sanada M, Nagai H, Horibe K, Tomita A, Suzuki K, Muramatsu H, Takahashi Y, Miyazaki Y, Matsumura I, Kiyoi H, Hosokawa Y, Mano H, Hayakawa F. Targeting MEF2D-fusion Oncogenic Transcriptional Circuitries in B-cell Precursor Acute Lymphoblastic Leukemia. Blood Cancer Discov. 2020 Jul;1(1):82-95. doi: 10.1158/2643-3230.BCD-19-0080. Epub 2020 Jun 10. PMID: 35015692.
Copy Download .nbib Format: NLM
Showing 421 to 429 of 429 entries